Evidence map›Paper›PMID 27198616›Full record

ArticleRedox report : communications in free radical research2017

Homocysteine pre-treatment increases redox capacity in both endothelial and tumor cells.

Elena Díaz-Santiago, Luis Rodríguez-Caso, Casimiro Cárdenas, José J Serrano, Ana R Quesada, Miguel Ángel Medina

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox report : communications in free radical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Elena Díaz-Santiagoa Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
Luis Rodríguez-Casoa Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
Casimiro Cárdenasa Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
José J Serranoa Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
Ana R Quesadaa Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
Miguel Ángel Medinaa Departamento de Biología Molecular y Bioquímica , Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga , Andalucía Tech , Spain.
Instituto de Investigación Biomédica de Málaga · ESInstituto de Investigación de Enfermedades Raras · ESUniversidad de Málaga · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe studied the modulatory effects of homocysteine pre-treatment on the disulfide reduction capacity of tumor and endothelial cells.

methodsHuman MDA-MB-231 breast carcinoma and bovine aorta endothelial cells were pre-treated for 1-24 hours with 0.5-5 mM homocysteine or homocysteine thiolactone. After washing to eliminate any rest of homocysteine or homocysteine thiolactone, cell redox capacity was determined by using a method for measuring disulfide reduction.

resultsHomocysteine pre-treatments for 1-4 hours at a concentration of 0.5-5 mM increase the disulfide reduction capacity of both tumor and endothelial cells. This effect cannot be fully mimicked by either cysteine or homocysteine thiolactone pre-treatments of tumor cells. DISCUSSION: Taken together, our data suggest that homocysteine can behave as an anti-oxidant agent by increasing the anti-oxidant capacity of tumor and endothelial cells.

Indexed as

AntioxidantsCell Line, TumorEndothelial CellsHomocysteineHumansNeoplasmsOxidation-ReductionAntioxidantsHomocysteinehomocysteine thiolactoneBovine aortic endothelial cellsCysteineHomocysteineHomocysteine thiolactoneMDA-MB231 breast cancer cellRedox

Identifiers

PMID27198616
PMCPMC6837415
OpenAlexW2406099377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.